Navigation Links
Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
Date:9/25/2008

U.S. PATENT OFFICE GRANTS PATENT # 7,422,864 FOR TECHNOLOGY USED IN CORGENIX NEXT GENERATION PREDICTIVE CARDIOVASCULAR DIAGNOSTIC PRODUCT LINE

DENVER, Sept. 25 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has received notification of U.S. Patent Office approval for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan. The technology is incorporated in the Company's AtherOx(R) product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease.

U.S. Patent # 7,422,864 was issued September 9, 2008. The patent Method for Measuring Oxidized LDL-CRP Complex and Measurement Kit, describes the binding of oxidized low-density lipoprotein (oxLDL) with C-reactive protein (CRP) resulting in oxLDL/CRP (CRP-AtherOx) complex formation, and the immunoassay method for measuring these complexes in blood. CRP is an inflammatory protein that has been associated with risk of cardiovascular disease. High levels of CRP can be found in many inflammatory and infectious disorders, but oxLDL/CRP complexes were more specific and predictive of atherosclerotic cardiovascular disease (Tabuchi et al. J Lipid Res 2007; 48:768-781).

The latest patent adds to previous U.S. patents (# 5,900,359 issued May 4, 1999, Method for Determination of Oxidized Lipoproteins and Use Thereof, and # 7,160,733 issued January 9, 2007, Ligand Specific to B2-glycoprotein I and Use Thereof. These patents described the specific interaction of B2-glycoprotein I with the oxidized form of low-density lipoprotein (oxLDL) leading to the formation of oxLDL/B2-glycoprotein I complexes (AtherOx). This interaction does not occur with the native or non-oxidized form of LDL. An immunoassay for the detection of the complexes was described which provides the basis for the AtherOx(R) test kits.

Douglass Si
'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Francisco, California (PRWEB) July 31, 2014 ... systems that inform therapeutic decision-making in oncology, today announced ... August 14, 2014 to discuss the Company's financial results ... provide an update about the business in the current ... audio call beginning on Thursday, August 14, 2014, at ...
(Date:7/31/2014)... 31, 2014 Rancho BioSciences , ... of Omicsoft’s Array Suite with tranSMART . ... able to send data in tranSMART to Array Suite ... versions of tranSMART including the new 1.2 release. ... and storage for the analysis of high dimensional quantification ...
(Date:7/31/2014)... MA (PRWEB) July 31, 2014 ... (UC) and collaboration company, is proud to announce ... (LMS). LMS complements Adobe Connect’s elearning tools to ... LMS delivers content with training tools for desktop ... eLearning with LMS is the perfect online training ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... , SOUTH PLAINFIELD, N.J., Sept. 2 PTC ... its option to collaborate on advancing drug discovery efforts on ... (Gene Expression Modulation by Small-molecules) technology. , , ... , , In September 2007, Celgene made ...
... , SAN DIEGO, Sept. 2 Results from ... developmental product candidates will be presented at the ... held at The Moscone Center in San Francisco on September 12-15, 2009. ... , , , Fidaxomicin ...
... , SOUTH SAN FRANCISCO, Calif., Sept. ... the first commercial sales of a new 20 microgram per ... York Heart Association Class III and IV pulmonary arterial hypertension ... Ventavis in half the volume, which is expected to reduce ...
Cached Biology Technology:PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 2Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 3
(Date:7/30/2014)... researchers from the University of Helsinki and the Universitat ... in mice morphological changes which have taken millions of ... the embryonic development of mice teeth, induced in the ... similar to those observed in the fossil registry of ... ago. , To modify the development of their ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
(Date:7/30/2014)... Limited today announced an across-the-board increase in Impact ... 2013 InCites Journal Citation Reports (Thomson Reuters, 2014) ... Journal , Essays in Biochemistry , ... all received increases in their Impact Factors. ... and published by Portland Press Limited. , 2014 ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2
... Studying thousands of patients, Japanese researchers have found a ... three cancers esophageal, head and neck, and lung. ... of developing these diseases. In the May issue ... the American Association for Cancer Research, scientists from Aichi ...
... A Swiss marine biologist and an Australian quantum physicist have ... Reef, Australia, can see a world invisible to all other ... have shown that mantis shrimp not only have the ability ... but have optimal polarisation vision a first for any ...
... in the February 2008 issue of HortScience offers new ... athletic fields ready for fall sports more quickly. Results ... pare down the usual 9- to 12-month waiting period ... autumn football traffic. Dr. John Stier, Associate Professor ...
Cached Biology News:Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2Shrimps see beyond the rainbow 2Shrimps see beyond the rainbow 3Establishing faster-growing, durable football fields 2
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
Biology Products: